Bone Morphogenetic Protein

Published results showed patients who received bone morphogenetic protein during single-level anterior lumbar interbody fusion had increased risk for symptomatic pseudarthrosis with no improvement in revision rates.

As understanding of pulmonary arterial hypertension grows and novel therapies emerge, the treatment of PAH appears to be entering a new era.

Use of bone morphogenetic protein in single-level lumbar fusion may have a higher risk profile than previously reported with non-significant benefits, according to results.